1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease. 1976

A E Fournier, and P J Bordier, and J Gueris, and J Chanard, and P Marie, and C Ferriere, and M Osario, and J Bedrossian, and H F de Luca

Four microgrammes of 1-alpha-hydroxycholecalciferol (1-alpha-OH D3) or 200 mug of 25-hydroxycholecalciferol (25-OH D3) were given orally every other day respectively to 10 uraemic patients (8 on chronic haemodialysis) for 1-12 weeks and to 3 patients on chronic haemodialysis for 4-8 weeks. A transilial bone biopsy and serial evaluation of serum immunoreactive PTH (iPTH) calcium phosphate and alkaline phosphatase were performed before and at the end of therapy. Both 1-alpha-OH D3 and 25-OH D3 (the latter at a 50 times higher dose) were able to depress hyperparathyroidism in two-thirds of the cases and to consistently improve the mineralisation defect. In no case did iPTH or the bone histomorphometric parameters return to normal, so that long term evaluation of these two drugs is warranted.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D012080 Chronic Kidney Disease-Mineral and Bone Disorder Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders. Renal Osteodystrophy,Renal Rickets,Rickets, Renal,CKD-MBD,Osteodystrophy, Renal,Chronic Kidney Disease Mineral and Bone Disorder,Osteodystrophies, Renal,Renal Osteodystrophies
D001846 Bone Development The growth and development of bones from fetus to adult. It includes two principal mechanisms of bone growth: growth in length of long bones at the epiphyseal cartilages and growth in thickness by depositing new bone (OSTEOGENESIS) with the actions of OSTEOBLASTS and OSTEOCLASTS. Bone Growth
D001862 Bone Resorption Bone loss due to osteoclastic activity. Bone Loss, Osteoclastic,Osteoclastic Bone Loss,Bone Losses, Osteoclastic,Bone Resorptions,Loss, Osteoclastic Bone,Losses, Osteoclastic Bone,Osteoclastic Bone Losses,Resorption, Bone,Resorptions, Bone
D002113 Calcification, Physiologic Process by which organic tissue becomes hardened by the physiologic deposit of calcium salts. Bone Mineralization,Calcification, Physiological,Physiologic Calcification,Mineralization, Bone,Physiological Calcification
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002130 Calcium Phosphates Calcium salts of phosphoric acid. These compounds are frequently used as calcium supplements. Phosphates, Calcium

Related Publications

A E Fournier, and P J Bordier, and J Gueris, and J Chanard, and P Marie, and C Ferriere, and M Osario, and J Bedrossian, and H F de Luca
July 1976, Harefuah,
A E Fournier, and P J Bordier, and J Gueris, and J Chanard, and P Marie, and C Ferriere, and M Osario, and J Bedrossian, and H F de Luca
January 1975, British medical journal,
A E Fournier, and P J Bordier, and J Gueris, and J Chanard, and P Marie, and C Ferriere, and M Osario, and J Bedrossian, and H F de Luca
October 1977, British medical journal,
A E Fournier, and P J Bordier, and J Gueris, and J Chanard, and P Marie, and C Ferriere, and M Osario, and J Bedrossian, and H F de Luca
September 1977, British medical journal,
A E Fournier, and P J Bordier, and J Gueris, and J Chanard, and P Marie, and C Ferriere, and M Osario, and J Bedrossian, and H F de Luca
December 1986, Zentralblatt fur Veterinarmedizin. Reihe A,
A E Fournier, and P J Bordier, and J Gueris, and J Chanard, and P Marie, and C Ferriere, and M Osario, and J Bedrossian, and H F de Luca
October 1979, Pediatric research,
A E Fournier, and P J Bordier, and J Gueris, and J Chanard, and P Marie, and C Ferriere, and M Osario, and J Bedrossian, and H F de Luca
December 1974, Journal d'urologie et de nephrologie,
A E Fournier, and P J Bordier, and J Gueris, and J Chanard, and P Marie, and C Ferriere, and M Osario, and J Bedrossian, and H F de Luca
April 1977, Lancet (London, England),
A E Fournier, and P J Bordier, and J Gueris, and J Chanard, and P Marie, and C Ferriere, and M Osario, and J Bedrossian, and H F de Luca
May 1992, Biochemical and biophysical research communications,
A E Fournier, and P J Bordier, and J Gueris, and J Chanard, and P Marie, and C Ferriere, and M Osario, and J Bedrossian, and H F de Luca
July 1981, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Copied contents to your clipboard!